Publications
12
Citations
119
Est. group size
~1
Recurring co-author estimate
Active years
10
Publishing since 2017
Zhouyang Lou's recent work focuses on cardiovascular disease and cholesterol management, particularly studying drugs that lower LDL cholesterol (a type of 'bad' cholesterol linked to heart disease), such as PCSK9 inhibitors, alirocumab, and inclisiran. Related work also touches on quality of life in patients with gout, a form of arthritis caused by uric acid buildup. This research relies on observational and real-world clinical practice data rather than laboratory experiments.
Publication output has been low and irregular over the past decade, with several years of zero or one paper, but shows a recent increase with three publications listed for 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study
European Heart Journal · 2026
- 26-A-12564-ACC EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING
Journal of the American College of Cardiology · 2026
- PCR89 PATIENT CHARACTERISTICS AND HEALTH-RELATED QUALITY OF LIFE AMONG CONTROLLED AND UNCONTROLLED GOUT PATIENTS: EVIDENCE FROM THE MEPS DATABASE
Value in Health · 2026
- Clinical Gastroenterology and Hepatology×1
- PEC Innovation×1
- European Heart Journal×1
- IEEE Transactions on Automation Science and Engineering×1
- Operations Research for Health Care×1
- Steven R. Counsell
Medicine · Indiana University
- Cathy C. Schubert
Medicine · Indiana University
- Sun Young Kim
Medicine · Purdue University West Lafayette
- Indrakshi Roy
Health Professions · Indiana University
- Andrew W. Brown
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile